Reddit Posts
Is their some good bargain plays in tech at this time
Mentions
Well it is still over 100% higher compared to where it was when I wrote this post. The Alzheimer's end of phase 2 meeting with the FDA went way better than expected (greenlit for both mild and moderate Alzheimer's with low p-tau217), which was the reason for the runup, but the BTD for DLB got rejected, which is the reason for the crash. In my opinion it still offers a great risk-reward ratio, but one definitely should not put more money into it than they can afford to lose, 1-2% of their portfolio at max.
Nothing much happening until next development, e.g. initiation of Phase 3 or partnership or EOP2 meeting for DLB...
A clock stop (even if it happened) is not a positive, it is a negative. It shows that they weren't satisfied by the data AVXL sent and they need more. Sure, it could be worse (instant denial), but you shouldn't spin it as a great thing. The same thing happened (although by FDA, not EMA) with CGTX-es BTD: they asked for more data, then in the end they denied their BTD for DLB.
Thank you, I was invested into them a couple of years ago, but when they were afraid to go for FDA approval even a year after their phase 2/3 trial I pulled out, because it seemed fishy. If you look up the EMA deadline you can see that they are way above it, so either they also think that something is fishy or they already denied it and AVXL simply didn't tell their investors (though hopefully the first). Also, as far as I know nowadays they are only representing the data of people with early Alzheimer's, which is a 1-200 thousand market on the US instead of the 7 million they aimed for and less than tenth of the people CGTX got Phase 3 approval with Zervimesine, all the while AVXL has a market cap of like 4-5 times compared to CGTX. Long story short, I like CGTX much better, even if their BTD for DLB got denied.
There are a couple of major changes: - The end of phase 2 meeting with the FDA for Alzheimer's disease went way vetter than I expected, they got greenlight for both mild and moderate Alzheimer's for low p-tau target groups. This means that the total addressable market in the US alone jumped to two and a half million people instead of roughly one hundred thousand. The FDA also told them that they can do two simultaneous 6 month Phase 3 trials if they want, which drastically reduces the time needed. This was the reason for the rally in recent weeks. - Todays news is that Breakthrough Therapy Designation for Lewy-Body Dementia got rejected. This is the reason for the crash. In my opinion there won't be any big news in the next couple of months, and for real big news we will probably have to wait a year or two now. This will be a patience game from now on, which means that the shareprice might even go lower. If you invest then you should know that this might be sideways for months, and obviously the core thesis remains the same: if the phase 3 trials succeed (either for DLB or Alzheimer's, though I am pretty sure that the management will prefer the Alzheimer's route first because of the FDA news) then this company will be worth $10+ billion in a couple of years. If they fail, then bankruptcy is definitely on the table and we will probably all lose our money. So treat this company as a high-risk high-reward lottery ticket, definitely do not put more money in than you can afford to lose (For example I lost 90% of my SAVA investment in mere minutes after they told that their trial failed)
See #4: Still awaiting End of P2 meeting for DLB, which by all measures should be thumbs up.
After the recent runup I am slowly reducing from 50% of my portfolio to 20% of my portfolio, which is still crazy high. I wouldn't recommend anyone to held more than low single percentages of their portfolio in CGTX, since the risk is still really high! The thesis haven't changed much, the end-of-phase 2 meetings for Alzheimer's went way better than I expected (they can go for both mild and moderate Alzheimer's eith low p-tau 217, which is an over 2 million people market in the US, also only two 6 month trials needed. I thought that they will only get permission for mild Alzheimer's, which would have been 100-200 thousand people market at max), but there are still no news about their DLB BTD approval which is definitely a red flag. Also, they obviously still haven't been able to secure a partner given their $30 million dilution. So yeah, there are both a lot of good and bad news. I'll intend to hold my remaining position, but if it would go up a lot (like over 10x) before phase 3 news I would definitely sell like half of it and let the other half ride. This is obviously still by far my largest holding, definitely don't be crazy like me and do not put 20-50% of your portfolio in it, put in low single digits percentage (1-3%) at max :D
EOP2 meeting for DLB week will definitely be related to BTD approval IMHO.
Thank you for this very high quality submission. I am one of those who has been focused on BTD approval (see my post in r/CGTXstock from yesterday), but more as a proxy for the long-term success of CT 1812 for the treatment of DLB and, hopefully, AD. Not so much as a short-term investment catalyst. MM didn’t seem to answer your question regarding the sufficiency of the data from two parallel six-month studies; what do you make of that?
Well my main thesis definitely changed somewhat with the recent news. The Alzheimer's news was way better than I expected. I expected only mild, but they let them use their drug for both mild to moderate with low p-tau 217. Mild Alz would have been a 100-200 thousand market in the USA, mild to moderate with low p-tau is over 2 million. Also, the FDA only wants two 6 month Phase 3 trials, which significantly reduces the time needed. Still, I hoped for the DLB BTD approval by now. I reduced my position since my post, but mostly because I was crazy overextended, basically half my portfolio was in CGTX. Right now roughly 1/3 of my portfolio is in it and in the next couple of weeks I intend to reduce it to 1/5 or so, or maybe even less. That would probably still mean millions of dollars profit with a successful phase 3, but I want to mitigate my risks since we are still talking about a biotech company. (With SAVA I lost almost half my portfolio in the past. Biotech is extremely risky.)
CGTX isn’t just another penny stock — it’s a derisked biotech with proven Phase 2 data, FDA alignment on accelerated Phase 3 trials, and a $50B+ market opportunity in DLB and Alzheimer’s. The upside is asymmetric: even after running from $0.75 (my entry point), the science and catalysts support $50–$150/share potential in the next 2–3 years. It is biotech, so it is high risk-high reward, but as it continues to derisk, the allure grows. Do your own DD, understand the science, the market, and the potential and you may change your mind. Or you may not - and that’s fine if it’s not your bag - find what is.
Your synopsis was superb, kudos! Hell, based on DLB alone the stock is undervalued. Add in ALZ and Geographic Atrophy and you have a massively undervalued biotech. Tomorrow the NAZ threat of delisting will be lifted. Funny thing, the day AFTER you wrote your post shares jumped 41% to a touch under three bucks. When one calculates their potential share of ALZ and DLB revenues then yes, the stock has massive upside. At $2.81 the market cap is about $200MM. Their sales would be in the billions, but probably less than 10B. Times a probable sales price of 4-7X revenues and well, get your calculator out. I am hoping in any partnership that we retain significantly over 50%, preferably 75-80% as the partner would still have huge revenue stream and many big pharma well of drugs patent protection is coming to an end inside 5-10 years. This is a cheap way for them to get into multiple, huge markets. A+ on your post.
I read that about 54% of BTD drugs achieve final approval, I would put that higher if their numbers were true in P2 for DLB. Which I believe they are, Plus Tau 217....if ONE gets approved you have a 20-100X return. Though I bought/sold in a few days for $21k profit bought back in. Ave cost $1.80-90 and shares are 2.82 a day or 2 day, Heading northbound......
I believe the stock will hit $10 with the inclusion of Breaththrough drug status for DLB. The decision is due ANY day now, Mind you there are only drugs to treat some Lewy bodies symptoms but nothing, repeat nothing to prevent progression, That alone is worth billions in revenue world wide/year, Add in the Tau217 market of ALZ and you have a potential $5-10 billion revenue company that could be sold for 5-7x topline revenue. Say $30B. Current market cap is $200 million. I own 27k shares and intend to see what happens. This is a potential once in a lifetime opportunity, BTW, I remember when Apple was at $4-5 share, Now 100X+ that. The next six months will be important and yesterday, 22nd Aug, showed what legs this can have with a 41% gain and no BTD yet! BTW, also own Anavex,
Excellent comparison, my personal valuation of CGTX is minimum $30 if both AD & DLB succeed, don't forget dry AMD, this market is even bigger imo.
1. Release of a PR statement detailing official minutes from the End-of-Phase 2 (EOP2) meeting, confirming FDA alignment. (Occurred - PR statement better than expected) 2. Federal Reserve rate cut could drive market fund inflows, potentially boosting CGTX. 3. PR announcement confirming EOP2 meeting is scheduled with FDA for DLB. 4. PR announcement confirming a successful EOP2 meeting for DLB and that CGTX and FDA are in alignment (Unofficial) 5. FDA grants BTD for CGTX’s DLB treatment, signaling strong regulatory support. 6. Confirmation from NASDAQ that CGTX has met the $1.00 listing requirement before the deadline. 7. PR statement outlining official minutes from the DLB EOP2 meeting confirming FDA alignment. 8. CGTX announces a strategic partnership agreement. 9. Launch of Phase 3 clinical trials for Zervimesine in AD and DLB. 10. Release of positive interim data or progress updates from ongoing clinical trials.
Indeed, totally agree - only positive news ahead. BTD decision will boost the price but it's not critical even if denied, the company will go for Fast Track instead. Delisting risk will be over in a few days. Fundamental shift is huge. CT1812 has shown to work for AD, DLB, and dry AMD (this is what most retail investors miss but it proves that it works for many diseases related to degenerative protein across the body.)
BTD approval decision in coming weeks. DLB EOP2 meeting with FDA to be announced + minutes (probably after BTD decision) Possible partnership in next few months
Still up 100% in the last 5 days and 150% in a month, a minor pullback like this is healthy. I wouldn't be surprised at all if we would have some down days before the NASDAQ compliance news and DLB news come out. I am still holding, actually increased my position to 185000 shares but as of now I am all out of dry powder, so I probably won't be increasing it more even if it dips. I won't care if it goes down though, the data and FDA news are out and there are literally two catalysts in two weeks, so I'll just lay on my back and wait :)
They saw effect only in post hoc analysis. Yes, it was pre-specified, but couldn’t one argue that is just clever p-hacking by announcing it in advance? And efficacy seems to really drop in Alzheimer’s even in sup-population raising concerns about durability. The nice thing is the FDA has agreed to a 6 month trial. Really lowers the bar. But if efficacy is not durable, which we’ll eventually see in extension data, this could really limit use. DLB data looks better on durability data, but time will tell.
Sorry, we are in such different worlds on almost everything you said. I don’t invest in a company to dabble. I do my diligence and then I make a significant investment. I don’t invest in biotech stocks to mitigate losses. Risk management is what my index funds are for. I certainly don’t do that in extremely binary companies like this - where the stock goes crazy or goes to zero. My question is a due diligence question. What makes this company so much more compelling than a BIVI or SAVA or ANVS or a whole list of others that have failed despite tantalizing data in early-to-mid stage companies? And as I look more carefully at the data now, what makes us think the effect will be durable? The DLB actually looks very good - but is it durable? However, as I do my due diligence, honestly just on the DLB data this company is wildly under-valued. It’s a shame they are pushing Alzheimer’s ahead of that, where the data is less convincing.
When is the DLB BTD decision?
IF both DLB and ALZ are approved at FDA and probably EMA/Europe then I can see a market cap of $5 Billion or so. Depends on sales. That will be 60x today's SP of about $1.20. So yeah, I would take $60 a share. About 10k shares here BTW.
Regarding partnership, CEO Lisa has hinted few times already March 20th:- we are **actively evaluating options** to fund our clinical trials, including potential partnering opportunities with pharmaceutical companies And most recently on Aug 7th:- “In addition, we expect FDA will have a decision on breakthrough designation for zervimesine in DLB in the third quarter 2025. **We expect these milestones will be valuable to potential partners as we continue to evaluate our options** to support development of zervimesine.”
| Claim | Status | | --------------------------------------------------- | ----------------------------------- | | FDA greenlight Phase 3 for mild & moderate AD | **Verified** | | Only two 6‑month trials needed (maybe simultaneous) | **Verified** | | 95% reduction in decline in low p‑tau subgroup | **Verified** | | Subgroup \~30% of US patients (2M+) | **Unverified** | | Stock “only up 7% today” (should be hundreds) | **Inaccurate** (actual \~30% surge) | | Breakthrough Therapy for DLB expected by end‑August | **Unconfirmed** |
Me too. If I was them, the most pragmatic approach (for partnership) would be to get P3 approval for AD and DLB trials, plus hopefully the BTD designation. Then you'll know what P3 trials will cost and the partner will have an understanding about lots of important details (timing, cost, approval likelihood, etc.). Waiting until these events to partner allows for a better deal for both sides. That's been my thesis for awhile. Next couple of months will be interesting.
Gotta flex a little bit… I’ve been accumulating this one and doing a lot DD for the past 9 months. Up to 110k shares with a $0.53 average. It’s a good chunk of my portfolio (much more than a flier), but of the hundreds of tickers I’ve researched, this seems like the best potential risk/return ratio. There’s been tough times, being down 60% for months. However, I always believed the science/results would shine through. At some point I do believe the market will accurately value this drug/company over $1B, and I plan on being there with as many shares as I can hold when it does. PS… a $1B market cap would be a SP of $16, although as others pointed out, even that would be VERY low for a working AD & DLB drug. Oh, and it even seems to work well for dry AMD, which is an awful condition where the only working treatment requires injections into the eyeball every couple months!
You should contact the company. They have an EAP program where participants definitely get the drug, but not sure if it’s for AD or DLB.
Too low, by far. The DLB market, given only treatment, could be worth billions in top line revenue alone/annum. Billions, 1.4 million suffer in USA alone.
With great ALZ and DLB results, especially Lewy, this is one to buy and keep. Get in now. A true, cheap SP find.
What about the $200M in non-dilutive funding from NIH/NIA grants? A significant portion of this has been earmarked for Phase 3 Alzheimer’s and DLB trials. Since they are only 6-months, cost should be ~$60-$80m. It’s possible they can cover this with their existing grant funding. My opinion, but I am not CFO of CGTX. Do your own DD before investing.
Me too, no need to sell with besr-in-class AD, fitst-in-class DLB candidates.
The biggest upcoming catalyst is undoubtedly: **2) Breakthrough Therapy Designation for DLB (Dementia with Lewy Bodies)** The results from phase 2 shows significant efficacy as presented yesterday (and since last December) CGTX's CT1812 has shown a superb improvements on all aspects of the symptoms. DLB is complicated and currently requires multiple approach to treat different symptoms, whereas CT1812 has shown a daily single dose oral pill. This is pending EOP2 meeting but will be announced any time in the future. Nevertheless, the outcome of phase 2 is truly remarkable and can be considered ground-breaking. Dr. Galvin is one of the pioneers in DLB studies and he is extremely convinced that this will change life of DLB patients and their caregivers. Anyway BTD approval will give super leverage for CGTX to attract partner or even seek for buyout opportunities, AD treatment as a 1+1 bonus for the buyer. RISKS :- During the earnings, I am anticipating an announcement of opening a door for Reverse split and may be Dilution (ATM or whatever), this is to secure the stable operation and normal procedures expected with clinical stage biotechs.
CGTX, time to fly, updated results on DLB
Presentation at AAIC is nothing new, only difference is that AAIC has selected CGTX's presentation to be presented at prime time as an oral presentation, company doesn't have a say in this regards, AAIC allocates them after assessing significance of the content. For example, CRVO's presentation was just a poster display with in person for explanation. Anyway, AAIC's presentation just shows how the experts in this field are regarding CT1812's findings and provides good leverage in longer term in terms of negotiation with partners or b/o. What is coming later is more important, clear roadmap for AD's PHASE 3 and BTD for DLB.
You are right, best bet is to play safe. Safe investment is to take some profit with a pop and may be re-enter after the earnings or downsize the position. CEO has already mentioned RS will be considered with monitoring the price. However, the company hasn't made any sign of movement yet despite approaching deadline, company also knows there are series of catalysts and will wait to see how the market reacts. And you are right, earnings are rarely good, not just RS in this case but with upcoming phase 3s they will need additional funding. CGTX's CEO Lisa Ricciardi has led several partnerships and mergers previously. Notably $1.03 billion deal with Roche and $29B with Medco and she spent many years with Pfizer. Clear pathway for phase 3 for both AD and DLB will provide good leverage to find a partnership or even buyout options. In this aspect, the AAIC this week will be quite important in terms of partnership discussions.
There are multiple ongoing phase 2 with CT1812, AAIC Oral presentation on 29th is for SHIMMER (DLB trial - more detail in my comment above) the link you shared is about SEQUEL, preliminary study to find whether CT1812 improves synaptic function in AD patients and whether this improvement can show a quantitative result (qEEG). The SEQUEL study was funded by NIH with $5.3M grant and the publish went mostly unnoticed despite a super positive result. You can research for the detail but to put it simply it showed CT1812's working mechanism actually improves functioning the brain on AD patients. This trial was done for short period of time (29 days) with small number of patients (16) and showed no adverse effects. The significance of SEQUEL is that CT1812 binds to the sigma‑2 receptor, allosterically changing its shape and displacing Aβ oligomers from neurons. This prevents toxic AβOs from disrupting synapses. What does it mean? Results of SEQUEL reveals more detail about CT1812's mechanism and will have positive impact on decisions from FDA.
It is true that it's up almost 400% from its lows, been climbing gradually with just a little pop with EOP2 meeting with FDA, and it's not done yet. AAIC Podium Presentation isn't really a news at all, it's just an added bonus along the way. Real deal is to come in August with official minute from FDA for EOP2 regarding AD treatment (which is highly popular subject among small cap bio and very likely to announce roadmap for Phase 3. CT1812 has shown a significant improvement for early AD patients specifically with low p-tau 237 group (early stage AD) and showed astonishing 95% of slow in decline for this low p-tau 237 group. This means patient with early AD can have much better quality of life for longer period of time. Caveat for AD treatment with CT1812 is that it doesn't work with already advanced AD patients. Further extended study for AD treatment is already on its way (Phase 2b) and will begin trials from this year. Phase 3 will be likely to be designed for low p-tau 237 groups. Anyway, we have yet to see FDA's minute but the company has already announced the meeting was positive. And the biggest deal is to come later in August with FDA's approval decision with DLB treatment using same CT1812, which showed staggering efficacy on all aspects of symptoms. DLB is a basically a buffet of Dementia, its biggest problem is hallucination and patient turning violent and the life of caretaker can be miserable, and it is combined with cognitive decline, motor decline, This can be a real breakthrough technology. It showed 82-86% reduction in NPI (hallucinations/anxiety/delusions), 91% reduction in CAF (variability of attention and alertness), 52% reduction in ADCS-ADL (Functional ability - daily tasks such as shower, dressing etc...), 62% reduction in MDS-UPDRS (Parkinsonism-related motor function) all results against the placebo, and most importantly, improvement of caregivers' distress was significant against placebo groups. Anyway, you can DYOR. 10,000@0.68
**New Deep Dive: Cognition Therapeutics ($CGTX)** Cognition is a microcap CNS company developing an oral Alzheimer’s and DLB drug, backed by $47M in NIH grants. It trades around a $40M market cap—effectively at cash—despite multiple mid-stage trials and near-term data catalysts. In this report, we cover: • The science behind sigma-2 receptor modulation • Valuation modeling (rNPV and peer comps) • Bull, bear, and base case outcomes • Why we assign a conviction score of 8.3/10 • Target valuation: $150–175M If CGTX delivers, we think it re-rates sharply. If not, the downside is mostly priced in. **Read the full analysis here:** [https://frisbyresearch.substack.com/p/1-undervalued-nih-backed-and-near](https://frisbyresearch.substack.com/p/1-undervalued-nih-backed-and-near)
Being realistic:- Further 20~30% increase likely to test $1.00 towards the end of the week. If IND for DLB approval is announced, we might see a little short lived spike 50~100%. It'll be short lived as many investors will cash in due to RS + dilution risk. Highly Speculative:- If IND approval is announced during AAIC with partnership on the horizon, we may see x2~ jump and RS/dilution risk will be minimised. If the partnership news is followed by FDA's positive EOP2 minute release in two weeks, it'll lead to another jump.
No point in guessing, but they have legit science behind and a few upcoming catalysts - A conference next week - FDA Minutes expected: August 2025 (firm decision on path) - Breakthrough designation for DLB: likely later in 2025
10% of my portfolio is in $CGTX, besides the conference next week, the next catalysts are: - FDA Minutes expected: August 2025 (firm decision on path) - Breakthrough designation for DLB: likely later in 2025
\-AAIC main podium presentaion for successful Phase 2 for DLB, \-IND approval for Phase 3 next week \-BTD approval for DLB (extremely likely) late Aug-Sep \- EOP2 FDA minute beginning of August
Next week - Phase 2 Success Podium Presentation at AAIC on July 29th for DLB (Dementia) Upcoming IND approval for DLB, announcement possibly next week during AAIC Early August - Positive EOP2 Minute with FDA and pathway to Phase 3 for AD (Alzheimer) Mid August to Early September - BTD approval for DLB (extremely high probabilty due amazing Phase 2 results)
Next week - Phase 2 Success Podium Presentation at AAIC on July 29th for DLB (Dementia) Upcoming IND approval for DLB, announcement possibly next week during AAIC Early August - Positive EOP2 Minute with FDA and pathway to Phase 3 for AD (Alzheimer) Mid August to Early September - BTD approval for DLB (extremely high probabilty due amazing Phase 2 results)
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC.... copied from yahoo news
Cognition Therapeutics A company in a clinical stage that develops medicines for the treatment of neurodegenerative diseases, announced that Dr. James E. Galvin, MPH, will present the results of phase 2 study "Shimmer" with Zervimesin (CT1812) in dementia with Lewy bodies (DLB) during an oral presentation at the International Conference of Alzheimer Association (AAIC). Dr. Galvin is director of the Miller Medical Medicine Faculty of Medicine Faculty of Medicine and was the director of the COG1201 Shimmer Study (NCT05225415). The presentation will take place on July 29, 2025, at 8 am (US East Time) at the prominent research session. Catalyst data accumulating .. Surely zervimesin will be a highly innovative drug especially for the Dementia of Lewy Bodies https://www.globenewswire.com/news-release/2025/07/16/3116291/0/en/Cognition-Therapeutics-Positive-Clinical-Data-from-Zervimesine-CT1812-Phase-2-Study-in-Dementia-with-Lewy-Bodies-DLB-will-be-Presented-in-a-Podium-Presentation-at-AAIC.html CGTX can surely be a 500x company!!
Cognition Therapeutics A company in a clinical stage that develops medicines for the treatment of neurodegenerative diseases, announced that Dr. James E. Galvin, MPH, will present the results of phase 2 study "Shimmer" with Zervimesin (CT1812) in dementia with Lewy bodies (DLB) during an oral presentation at the International Conference of Alzheimer Association (AAIC). Dr. Galvin is director of the Miller Medical Medicine Faculty of Medicine Faculty of Medicine and was the director of the COG1201 Shimmer Study (NCT05225415). The presentation will take place on July 29, 2025, at 8 am (US East Time) at the prominent research session. Catalyst data accumulating .. surely zervimesin will be a highly innovative drug especially for the Dementia of Lewy Bodies https://www.globeNewswire.com/news-release/2025/07/16/3116291/0/cognition-therapeutics-postitive-clinical-data-from-z Ervimesine-CT1812-Phase-2-Study-in-Dementia-With-Lewy-Bodies-Dllb-Will-Be-Presented-in-a-Podium-Presentation-a-Aaic.html CGTX can surely be a 500x company as you well calculated
Cognition Therapeutics uma empresa em estágio clínico que desenvolve medicamentos para o tratamento de doenças neurodegenerativas, anunciou que o Dr. James E. Galvin, MPH, apresentará os resultados do estudo de Fase 2 "SHIMMER" com zervimesina (CT1812) em demência com corpos de Lewy (DLB) durante uma apresentação oral na Conferência Internacional da Associação de Alzheimer (AAIC). O Dr. Galvin é diretor do Centro Integral de Saúde Cerebral da Faculdade de Medicina Miller da Universidade de Miami e foi o diretor do estudo COG1201 SHIMMER ( NCT05225415 ). A apresentação ocorrerá em 29 de julho de 2025, às 8h (horário do leste dos EUA), na Sessão de Pesquisa em Destaque. Dados catalisadores se acumulando .. Com toda certeza a Zervimesina será um medicamento altamente inovador principalmente para Demência de Corpos de Lewy https://www.globenewswire.com/news-release/2025/07/16/3116291/0/en/Cognition-Therapeutics-Positive-Clinical-Data-from-Zervimesine-CT1812-Phase-2-Study-in-Dementia-with-Lewy-Bodies-DLB-will-be-Presented-in-a-Podium-Presentation-at-AAIC.html CGTX com certeza poderá ser uma empresa de 500x como você bem calculou
Sold my DLB calls way too early, not happy about that. FUCK.
ya my richard hard for DLB, surprised not more are talking about it. $75 c expiry 12/20 will be up over 400% if it holds
The nice thing about DLB $75 12/20 calls is that it had such low IV and still a month out. These will print nicely tomorrow.
did DLB release AI sound or what?
Omfg I threw 3k at DLB calls before close. LFG
Bought calls on DLB before close
My focus going into the new year is to do detailed reviews lf my 3 lowest-confidence holdings to see if I should upgrade them, sell, or stay put: $DLB, $SHC, $DOCS. And I have two companies on my watchlist that I want to also review to see if I should start a position: $SKYH, $XMTR.
This is a possibility. One of the drawbacks to my DLB stake is that there’s room to cut G&A and Marketing but the holding family keeps things as is. Margins can absolutely improve to return shareholder value, but the family has a slow & steady approach to growing the company through industry cycles. R&D continues to stay high as a percentage of gross sales, which exemplifies the company strategy. This makes any intelligent investor more confident in the long term approach, but not seeing excess margin squeezed out means capital can’t be appropriated efficiently.
DLB $90c couple months out. I have no thesis other than something I saw scanning some shit let’s ride
Dolby $DLB regaining most of its post-earnings drop on news of S&P madcap 400 inclusion
ASML or DLB if they continue to drop. I am happy to add on during market volatility.
Doubled down on DLB after earnings, and bought into HWKN this morning. Small caps have a lot to gain in this environment. I might buy some more Berkshire later when it inevitably dips post ATH.
It’s a little more complicated than that. Yes they did print money, but they also relied on other countries (China, UK, Japan, Middle Eastern countries, and more) to buy US debt. The US government bails out US companies, but in doing so they need other governments to bail out the US government and this happened in 08 as well. https://www.wsj.com/articles/BL-DLB-3968 “The bailout has revealed the ignorance of many Americans about the the financial food chain. Just like consumers who believe beef comes from shrink-wrapped packages in the supermarket rather than actual cows, many Americans have long acted as though money comes from ATM machines and plastic cards. The credit crisis, with its top-to-bottom ravaging of the financial system, made that naivete impossible to maintain: the average citizen's borrowed money comes from banks, and those banks borrow from Wall Street investment banks, and Wall Street investment banks borrow from the government, and the government borrows from China, Japan and the Middle East. A flat-screen TV bought in Dubuque is financed with part of the life savings of a salaryman in Tokyo.”
Fuck Dolby atmos. I set up a 120” projector in my bedroom, with a fucking sound system that requires eArc, and there’s only one fucking adapter made by some company in Taiwan that will push the signal needed for Atmos. So, I got it. Worked for a while, and now audio is finicky. Fuck you, puts on DLB.
how is DLB never mentioned as a metaverse play. Company is a f'n monopoly...
Here are my picks: Pitney-Bowes (PBI) -- potential turnaround play for a legacy mail and postage company, like Stamps.com. Dolby Technologies (DLB) -- still a leader in surround sound and experience equipment. Energizer Holdings (ENR) -- high margin battery to consumer business and some diversification into the auto parts business. why Energizer hasn't ventured into EV battery production boggles me SPDR Financial Select Fund (XLF) -- well, the Fed has to raise rates, right? So banks / financial companies can only go up from here.
I've tossed a decent chunk of change (for me, anyways...) towards stocks like ATVI, DLB, WAL, and picked up a few new ones like SWKS, MRTN, and LZB. Their fundamentals appear to be excellent, they have good growth potential, and their P/E ratios seem pretty good to me.
I disagree, there are dozens of such firms out there that fit the bill. Off the top of my head, DISH, DLB, LDOS, and RTX, just to name a few.
#Ban Bet Lost /u/SK_customs (3/1) made a bet that DLB would go to 82.0 when it was 88.95 and it did not, so they were banned for a week.
**Ban Bet Created:** **/u/SK_customs** bet **DLB** goes from **88.95** to **82.0** before **2021-11-17 22:40:28.433017-05:00**
Excited to collect on my DLB puts.
At least my DLB puts will print
Should’ve chosen a put for DLB like I first planned 🤦🏾♂️
Anyone thinking about DLB for earnings? Pretty boomer but if earnings are good I see another setup like CAR. u/giorgio_95, got any thoughts on this? I know you caught that other similar setup recently, can’t remember the ticker.
Thing is, bank price targets are generally wildly [overoptimistic](https://www.wsj.com/articles/BL-DLB-25041).
https://www.wsj.com/articles/BL-DLB-4713
I will continue to SHILL DLB until it reaches $125. Dolby atmos, Dolby vision, all of their products are royalty generators. Take for existence AAPL, they now use Dolby vision and atmos, and spatial audio in all of their current shipping products, even if the end user doesn’t use it, DLB is still getting paid a royalty. Once AR/VR starts gaining real traction and immersive experience is what will set them apart, and who better positioned to create an immersive a/v experience than DLB? Also have you been to a Dolby theater? They are far superior to the regular movie experience and are only a couple bucks more. Then there’s SONOs who started the atmos in soundbar trend pretty much. Long live DLB. They sold off recently because they’re CFO retired. I have peeled painstakingly through the financials and they are a CASH COW. Be aware, extremely low volume most days, but I think there’s some meat on the bones. I told everyone to buy $99 May 14 calls in early Feb, and these PRINTED.
My three favorite ex-SPACs are SOFI, MAPS, and MP. Normal stock would be DLB but I don't have a position because I am dumb. Just a big fan of the company is all :)
My choices are DLB, IMAX, and SNE for entertainment
DLB is a quiet volcano that is about to erupt
DLB dipped because the CFO retired… I’m buying this dip
DLB. They’re basically a monopoly among companies that license audio codecs and every major streaming service uses them and pays them royalties. Also expanding into music.
Saw Dolby logo, bought DLB. That's the one we're squeezing right?
My first dd was on DLB and I posted it a few weeks ago, only got like 50 upvotes: https://reddit.com/r/wallstreetbets/comments/lhgpwj/dlb_and_why_it_is_undervalued_for_what_it_does/ during the recent dip it barely sold off, reached a new 52wk high today Pretty proud of myself even though it didn’t get very much exposure
DLB has been on a constant tear fellas
Why will anyone listen to Insana? He's a failure. The facts don't lie [https://www.wsj.com/articles/BL-DLB-3275](https://www.wsj.com/articles/BL-DLB-3275)
I made my first DD post about DLB a couple weeks ago after spending time digging through their financials...(https://reddit.com/r/wallstreetbets/comments/lhgpwj/dlb_and_why_it_is_undervalued_for_what_it_does/) Throughout the dips it hasn’t been sold, it has steadily gone up, and today it hit a new ATH.. I am proud of myself
DLB is at a top already and has very little short interest. What makes these things pop is catching enough people pushing for the $2 put price improvement from $8 to $6 and crushing them quickly so it pushes up fast, and then just don't sell when it pauses and let em buy very expensive puts again this time.
DLB and AMC go hand in hand. DLB is a cash cow
Buying LULU, ON, AMAT, MRVL, APHA, DLB, ADI, TSM, NXPI tomorrow 🤑🤑🤑